Safely Switching From Natalizumab To Ocrelizumab In Patients With Ms At Risk Of Pml

Safely switching from natalizumab to ocrelizumab in patients with MS at risk of PML

Comparing exit strategies in natalizumab-responders at high risk for PML

Challenges in switching from natalizumab in RRMS

Dr Paul Molyneux - Managing PML risk in patients treated with Natalizumab.

At the Limits - Leading Medical Education

Extending Natalizumab's Use Without Increasing Risk to MS Patients

Risk Analysis of Natalizumab in Progressive Multifocal Leukoencephalopathy

What You Need to Know About Natalizumab (Tysabri®)

National MS Society

Prof Gavin Giovannoni: Managing MS remotely during the COVID-19 pandemic

Neurology Academy

Evaluating Natalizumab’s Risk-Benefit Profile in MS

Tysabri PML Risk & Extended Interval Dosing

Dr. Brandon Beaber

Benefits of SC natalizumab in MS

2nd PML Case With Ocrevus Reported by Genentech

Dr. Brandon Beaber

The comparative effectiveness of natalizumab and ocrelizumab in naïve relapsing remitting MS

Long-term results of ocrelizumab in treatment-naive patients with early relapsing MS

Tysabri: PML Risk Thought Experiment

Aaron Boster MD

Updates on natalizumab and anti-CD20 antibodies for MS

Review of Natalizumab for MS

Extending Natalizumab's Use Without Increasing Risk to Patients

Work productivity improves in patients with RRMS treated with ocrelizumab

CMSC: Comparative Effectiveness of Switching from Natalizumab to a Moderate VS High-Efficacy DMT

Consortium of MS Centers TV